» Articles » PMID: 15367885

Orthotopic Transplantation Models of Pancreatic Adenocarcinoma Derived from Cell Lines and Primary Tumors and Displaying Varying Metastatic Activity

Overview
Journal Pancreas
Specialty Gastroenterology
Date 2004 Sep 16
PMID 15367885
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To establish a series of clinically relevant orthotopic transplantation models of human pancreatic adenocarcinoma from both cell lines and primary tumors under uniform experimental conditions.

Methods: Ten pancreatic cancer cell lines and 12 primary tumors were orthotopically transplanted in SCID mice. The cell lines and xenografts were characterized for K-ras, BRAF, p53, p16, and DPC4 aberrations employing direct sequencing, immunohistochemistry, and Western blotting.

Results: All xenografts showed high intrapancreatic tumorigenicity and extensive local tumor growth, and each showed a unique behavioral and genetic profile. Tumor characteristics were retained during serial passaging. The cell line-derived xenografts represented the entire expected range of histologic differentiation. Although the overall metastatic rate was moderate to high, the metastatic pattern varied; 4 cell lines showed a high metastatic rate to the liver. The primary tumor-derived xenografts retained their similarity to the corresponding original donor tumors with regard to histologic presentation and biologic behavior. K-ras, p53, p16, and DPC4 aberrations were revealed in 80%, 70%, 50%, and 40% of cell lines and 100%, 33%, 75%, and 58% of primary tumor derived xenografts, respectively. No BRAF mutations were present. The metastatic behavior of the xenografts was significantly associated with the degree of histologic differentiation, number of genes altered, and p53 status.

Conclusions: The new models reflected the wide range of patho-biological features and genetic alterations that characterize human pancreatic cancer and may be used collectively or selectively as a markedly improved in vivo tool for preclinical and molecular studies of pancreatic cancer.

Citing Articles

Novel Concept of Electrocoagulation and Tumor Cell Implantation: Creation of Minimally Invasive Orthotopic Murine Model of Pancreatic Cancer.

Katuwal B, Aleissa M, Varshney N, Jacobs M, Mittal V, Bhullar J JSLS. 2025; 28(4.

PMID: 39831272 PMC: 11741199. DOI: 10.4293/JSLS.2024.00048.


Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.

Toyoda T, Miura N, Kato S, Masuda T, Ohashi R, Matsushita A Cancer Sci. 2024; 115(11):3622-3635.

PMID: 39259678 PMC: 11531968. DOI: 10.1111/cas.16302.


Patient-Derived Xenografts: Historical Evolution, Immunocompromised Host Models, and Translational Significance.

Thompson J, Saad M Methods Mol Biol. 2024; 2806:1-8.

PMID: 38676791 DOI: 10.1007/978-1-0716-3858-3_1.


Evaluation of Helium Ion Radiotherapy in Combination with Gemcitabine in Pancreatic Cancer In Vitro.

Cepni B, Tessonnier T, Dokic I, Brons S, Tawk B, Mairani A Cancers (Basel). 2024; 16(8).

PMID: 38672579 PMC: 11049166. DOI: 10.3390/cancers16081497.


Research progress in the establishment of pancreatic cancer models and preclinical applications.

Wu W, Wen K, Zhong Y Cancer Innov. 2023; 1(3):207-219.

PMID: 38089760 PMC: 10686130. DOI: 10.1002/cai2.31.